Exelixis Slashes Staff Again, Focuses All Internal Development on XL184
This article was originally published in The Pink Sheet Daily
As many as 65% of the oncology biotech's employees could be shown the door as the company ceases research on all but one drug candidate.
You may also be interested in...
Panelists with a variety of strategic motives met to discuss the pros and cons of business models at the Cancer Progress Meeting in New York City. The group represented both new and old firms, including some that perform research and some that license drugs.
The biopharma industry must think differently about funding high-risk/reward development of drug candidates against novel targets. Multiplexing Phase II proof-of-concept trials can light a path toward lower-risk pivotal studies and provide a model for building biotechs to deliver what patients, providers, payors, and investors all want: solutions.
Two venture firms bet on the Scottish university spin-out, now based California, as it develops pro-drugs activated by a specific enzyme family.